Platelet-rich plasma (PRP) has shown promise in enhancing nerve growth and improving gland function in patients with dry eye disease (DED) and neuropathic pain. A novel formulation of PRP eye drops demonstrated significant improvements in symptoms and signs compared to traditional treatments.
Background
Expand on the limitations of current DED treatments to highlight the need for PRP.
Data Highlights
Recent studies have indicated that PRP eye drops significantly improve Ocular Surface Disease Index (OSDI) scores and superficial corneal staining in DED patients compared to autologous serum (AS) drops.
Key Findings
PRP contains a 20-fold higher concentration of nerve growth factors compared to AS.
PRP eye drops can alleviate neuropathic pain associated with DED.
Innovative storage methods for PRP maintain its efficacy while preventing clotting and bacterial growth.
Clinical trials have shown PRP to outperform conventional artificial tears in symptom relief and ocular surface healing.
Corneal confocal microscopy (CCM) studies confirm that DED can cause significant corneal nerve damage, correlating with pain levels.
Clinical Implications
Clinicians should consider PRP as a viable treatment option for patients with moderate to severe DED, particularly those with neuropathic pain. The development of effective PRP formulations can enhance patient outcomes and provide an alternative for those unresponsive to standard therapies.
Conclusion
Reiterate the importance of further research and potential future applications of PRP in ophthalmology.
Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.
This article will examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, and offer guidance to practitioners who seek to expand their therapeutic options.
